IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+11.33%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$1.07B
AUM Growth
+$1.07B
(+19%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
9.88%
Top 10 Holdings %
Top 10 Hldgs %
45.5%
Holding
98
New
18
Increased
24
Reduced
16
Closed
24
Top Buys
| 1 |
Quest Diagnostics
DGX
|
$26.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$26.3M |
| 3 |
Cardinal Health
CAH
|
$23.5M |
| 4 |
Eli Lilly
LLY
|
$19.5M |
| 5 |
Charles River Laboratories
CRL
|
$17.4M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$19.6M |
| 2 |
Ascendis Pharma
ASND
|
$15.6M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$12.8M |
| 4 |
Krystal Biotech
KRYS
|
$10.8M |
| 5 |
Boston Scientific
BSX
|
$10.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Exact Sciences
EXAS
$9.33B
| $5.31M | 0.49% |
+100,000
| New | +$5.31M |
|
52
Waters Corp
WAT
$17.3B
| $5.24M | 0.48% |
15,000
-5,000
| -25% | -$1.75M |
|
53
Glaukos
GKOS
$5.42B
| $5.16M | 0.47% |
+50,000
| New | +$5.16M |
|
54
Elanco Animal Health
ELAN
$8.62B
| $5M | 0.46% |
+350,000
| New | +$5M |
|
55
Cooper Companies
COO
$13.3B
| $4.98M | 0.46% |
+70,000
| New | +$4.98M |
|
56
CRISPR Therapeutics
CRSP
$4.82B
| $4.86M | 0.45% |
100,000
-50,000
| -33% | -$2.43M |
|
57
Protara Therapeutics
TARA
$125M
| $4.24M | 0.39% |
1,400,000
| – | – |
|
58
Biohaven
BHVN
$1.71B
| $4.23M | 0.39% |
300,000
+125,000
| +71% | +$1.76M |
|
59
Sana Biotechnology
SANA
$759M
| $4.1M | 0.37% |
1,500,000
-500,000
| -25% | -$1.37M |
|
60
Ultragenyx Pharmaceutical
RARE
$3.04B
| $3.64M | 0.33% |
+100,000
| New | +$3.64M |
|
61
Scholar Rock
SRRK
$3.3B
| $3.54M | 0.32% |
100,000
-25,000
| -20% | -$886K |
|
62
Nurix Therapeutics
NRIX
$723M
| $3.53M | 0.32% |
310,000
+35,000
| +13% | +$399K |
|
63
Jasper Therapeutics
JSPR
$44.2M
| $3.27M | 0.3% |
590,000
+15,000
| +3% | +$83.3K |
|
64
Catalyst Pharmaceutical
CPRX
$2.42B
| $3.26M | 0.3% |
150,000
| – | – |
|
65
Alkermes
ALKS
$4.95B
| $2.86M | 0.26% |
100,000
-50,000
| -33% | -$1.43M |
|
66
Terns Pharmaceuticals
TERN
$651M
| $2.61M | 0.24% |
700,000
| – | – |
|
67
Arcus Biosciences
RCUS
$1.24B
| $2.44M | 0.22% |
+300,000
| New | +$2.44M |
|
68
Oscar Health
OSCR
$4.57B
| $2.14M | 0.2% |
100,000
-100,000
| -50% | -$2.14M |
|
69
Tenax Therapeutics
TENX
$27.5M
| $962K | 0.09% |
167,000
| – | – |
|
70
Alto Neuroscience
ANRO
$97.7M
| $880K | 0.08% |
400,000
| – | – |
|
71
Arcellx
ACLX
$3.95B
| – | – |
0
| – | – |
|
72
Arrowhead Research
ARWR
$3.84B
| – | – |
-175,000
| Closed | -$2.23M |
|
|
73
Ascendis Pharma
ASND
$12.1B
| – | – |
-100,000
| Closed | -$15.6M |
|
74
BridgeBio Pharma
BBIO
$9.91B
| – | – |
-100,000
| Closed | -$3.46M |
|
75
Becton Dickinson
BDX
$54.3B
| – | – |
-20,000
| Closed | -$4.58M |
|